Last reviewed · How we verify

TAPINAROF — Competitive Intelligence Brief

TAPINAROF (TAPINAROF) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aryl Hydrocarbon Receptor Agonist [EPC].

marketed Aryl Hydrocarbon Receptor Agonist [EPC] aryl hydrocarbon receptor (AhR) Small molecule Live · refreshed every 30 min

Target snapshot

TAPINAROF (TAPINAROF). Tapinarof activates the aryl hydrocarbon receptor (AhR), but the exact mechanisms of its therapeutic effects are unknown.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TAPINAROF TARGET TAPINAROF marketed Aryl Hydrocarbon Receptor Agonist [EPC] aryl hydrocarbon receptor (AhR) 2022-01-01
Tapinarof Cream 1% Tapinarof Cream 1% Teva Pharmaceuticals USA phase 3 Topical aryl hydrocarbon receptor agonist Aryl hydrocarbon receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aryl Hydrocarbon Receptor Agonist [EPC] class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAPINAROF — Competitive Intelligence Brief. https://druglandscape.com/ci/tapinarof. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: